Search results for "Infarction"

showing 10 items of 1208 documents

Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke.

2010

Abstract No study has yet evaluated the relationship between arterial stiffness indexes and immuno-inflammatory pathway in patients with an acute cardiovascular or cerebrovascular event. The aim of our study was to evaluate in patients with acute ischemic stroke the relationship between immune-inflammatory markers and arterial stiffness indexes. Methods 107 subjects with acute ischemic stroke and 107 controls without stroke. We evaluated plasma levels of C-reactive protein (CRP), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEmbolismTissue plasminogen activatorVon Willebrand factorIschemiaInternal medicinevon Willebrand FactormedicineHumanscardiovascular diseasesStrokePulse wave velocityAgedAged 80 and overInflammationbiologybusiness.industryCerebral infarctionMiddle Agedmedicine.diseaseAtherosclerosisischemic stroke arterial stiffnessSurgeryStrokeCarotid ArteriesImmune SystemAcute Diseasecardiovascular systemArterial stiffnessCardiologybiology.proteinCytokinesAortic stiffnessFemaleCardiology and Cardiovascular MedicinebusinessPlasminogen activatorcirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct

Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years

2020

Serum uric acid (SUA) levels discriminating across the different strata of cardiovascular risk is still unknown. By utilizing a large population-based database, we assessed the threshold of SUA that increases the risk of total mortality and cardiovascular mortality (CVM). The URRAH study (Uric Acid Right for Heart Health) is a multicentre retrospective, observational study, which collected data from several large population-based longitudinal studies in Italy and subjects recruited in the hypertension clinics of the Italian Society of Hypertension. Total mortality was defined as mortality for any cause, CVM as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internaepidemiology; heart failure; humans; risk; uric acid; Cause of Death; Female; Humans; Italy; Male; Middle Aged; Mortality; Practice Patterns Physicians'; Quality Improvement; Risk Assessment; Risk Factors; Uric Acid; Cardiovascular Diseases; Hypertension; Hyperuricemiaheart failurePractice PatternsHyperuricemia030204 cardiovascular system & hematologyepidemiology; heart failure; humans; risk; uric acidRisk AssessmentSudden cardiac death03 medical and health sciences0302 clinical medicineuric acidRisk FactorsInternal medicineCause of DeathEpidemiologyInternal MedicineMedicine030212 general & internal medicineHyperuricemiaMyocardial infarctionhumanMortalityPractice Patterns Physicians'humansStrokeriskEpidemiology heart failure humans risk uric acid.Physicians'business.industryProportional hazards modelHazard ratioUric acid cardiovascular mortality epidemiologyMiddle Agedmedicine.diseaseQuality ImprovementItalyCardiovascular DiseasesHeart failureHypertensionFemaleepidemiologybusiness
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct

Evaluation of post-myocardial infarction regional and global left ventricular function by monoplane ventriculography: superiority of right versus lef…

1996

OBJECTIVES To study the significance of serial quantitative regional wall motion analysis, volumes, and ejection fraction findings as well as their prognostic implications derived from cineventriculography in 30 degrees right anterior oblique (RAO) projection in comparison with 60 degrees left anterior oblique (LAO) projection in post-myocardial infarction patients. Ventriculographic left ventricular parameters are accepted surrogates of mortality in myocardial infarction. Nowadays, in contrast to a biplanar approach in most institutions and clinical trials, the investigation is reduced to monoplanar ventriculography. However, it is not known whether the relevance of the two established pro…

Malemedicine.medical_specialtyStreptokinaseMyocardial InfarctionInfarctionPost myocardial infarctionVentricular Function LeftInternal medicineMedicineHumansMyocardial infarctionAngioplasty Balloon CoronaryVentricular remodelingProjection (set theory)Ejection fractionbusiness.industryGated Blood-Pool ImagingStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseThrombosisSurvival AnalysisEvaluation Studies as TopicCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugCoronary artery disease
researchProduct

Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.

1999

Abstract Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. Methods and Results Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal card…

Malemedicine.medical_specialtyStreptokinasemedicine.medical_treatmentMyocardial InfarctionAnginaCohort StudiesFibrinolytic AgentsRecurrenceAngioplastyInternal medicineMedicineHumansStreptokinaseThrombolytic TherapyMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassAgedbusiness.industryOdds ratioThrombolysisMiddle Agedmedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorConfidence intervalRecombinant ProteinsCerebrovascular DisordersCardiologySaruplaseFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Differentiation between acute and chronic myocardial infarction by means of texture analysis of late gadolinium enhancement and cine cardiac magnetic…

2017

[EN] The purpose of this study was to differentiate acute from chronic myocardial infarction using machine learning techniques and texture features extracted from cardiac magnetic resonance imaging (MRI). The study group comprised 22 cases with acute myocardial infarction (AMI) and 22 cases with chronic myocardial infarction (CMI). Cine and late gadolinium enhancement (LGE) MRI were analyzed independently to differentiate AMI from CMI. A total of 279 texture features were extracted from predefined regions of interest (ROIs): the infarcted area on LGE MRI, and the entire myocardium on cine MRI. Classification performance was evaluated by a nested cross-validation approach combining a feature…

Malemedicine.medical_specialtySupport Vector MachineMyocardial InfarctionContrast MediaMagnetic Resonance Imaging CineInfarctionGadolinium030204 cardiovascular system & hematologySensitivity and Specificity030218 nuclear medicine & medical imagingDiagnosis DifferentialTECNOLOGIA ELECTRONICA03 medical and health sciences0302 clinical medicinePolynomial kernelCardiac magnetic resonance imagingmedicineHumansLate gadolinium enhancementRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesCardiac MRIChronic myocardial infarctionReceiver operating characteristicmedicine.diagnostic_testbusiness.industryMyocardiumReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseSupport vector machineClassification Myocardial infarctionROC CurveTexture analysisArea Under CurveAcute DiseaseChronic Diseasecardiovascular systemFemaleRadiologyNuclear medicinebusinessAlgorithmsMagnetic Resonance Angiography
researchProduct

Programmed death-1 (PD-1): A novel mechanism for understanding the acute immune deregulation in ST-segment elevation myocardial infarction

2014

Malemedicine.medical_specialtySwinemedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMyocardial InfarctionPercutaneous Coronary InterventionImmune systemInternal medicinemedicineAnimalsHumansST segmentProspective StudiesMyocardial infarctionAgedMechanism (biology)business.industryPercutaneous coronary interventionMiddle Agedmedicine.diseaseProgrammed Cell Death 1 ReceptorCardiologyFemaleProgrammed death 1ComprehensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention.

2017

Malemedicine.medical_specialtyTicagrelorPrasugrelAdenosinemedicine.medical_treatmentTreatment outcomeMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicinemedicineHumansIn patient030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionRetrospective cohort studyGeneral MedicineMiddle AgedNSTEMITreatment OutcomeEmergency medicineCardiologyPurinergic P2Y Receptor AntagonistsObservational studyFemalebusinessCardiology and Cardiovascular MedicineTicagrelorPrasugrelPrasugrel Hydrochloridemedicine.drugJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct